Table 2.
Preclinical studies investigating the effect of CBD on neuropathic and nociceptive pain in vivo
| Citation | Animal | Model | Treatment(s) | Treatment Effect |
|---|---|---|---|---|
| Neuropathic Pain | ||||
| De Gregorio et al., (2019) [51] | Wistar rats | SNI | 5 mg·kg-1·d-1, s.c. 7 d | CBD sig. decreased mechanical allodynia on Tx day 7. |
| Casey et al., (2017) [29] | C57BL/6 mice | CCI | 30 mg·kg-1, s.c. | CBD sig. decreased mechanical allodynia 2 h, but not 0.5, 1, 4 or 6 h, post-Tx compared to baseline. |
| 0.01, 0.1, 1, 10 or 100 mg·kg-1, s.c. | CBD dose-dependently decreased mechanical and cold allodynia. | |||
| King et al., (2017) [101] | C57BL/6 mice | CT (Paclitaxel) | 0.625–20 mg·kg-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7 | 1 and 20 mg·kg-1 CBD sig. attenuated the development of mechanical allodynia measured on Tx days 9 and 14, but not 21. |
| CT (Oxaliplatin) | 1.25–10 mg·kg-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7 | 1.25–10 mg·kg-1 CBD sig. attenuated the development of mechanical allodynia measured on Tx days 2, 4, 7 and 10. | ||
| CT (Vincristine) | 1.25–10 mg·kg-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7 | CBD did not attenuate the development of CT-induced mechanical allodynia measured on Tx days 5, 10, 15 and 22. | ||
| Harris et al., (2016) [78] | C57BL/6 mice | CT (Cisplatin) | 2 mg·kg-1, i.p. | CBD sig. decreased tactile allodynia 1 h post-Tx. |
| 0.5, 1 or 2 mg·kg-1, i.p. 30 min prior to CT every second day for 12 d | CBD did not attenuate the development of CT-induced tactile allodynia measured on Tx days 6, 10 and 12. | |||
| Ward et al., (2014) [187] | C57BL/6 mice | CT (Paclitaxel) | 2.5 or 5 mg·kg-1·d-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7 | 2.5 and 5 mg·kg-1·d-1 CBD attenuated the development of CT-induced mechanical allodynia. |
| Toth et al., (2010) [174] | CD1 mice | STZ Diabetes | 0.1, 1 or 2 mg·kg-1·d-1, i.n. 3 months | 1 and 2 mg·kg-1·d-1 CBD sig. attenuated the development of thermal and tactile hypersensitivity compared to 0.1 mg·kg-1·d-1 CBD. |
| 2 mg·kg-1·d-1, i.n. 1 month | CBD did not alleviate developed thermal or tactile hypersensitivity. | |||
| 1, 10 or 20 mg·kg-1·d-1, i.p. 3 months | 20 mg·kg-1·d-1 CBD sig. attenuated the development of thermal and tactile hypersensitivity compared to 1 mg·kg-1·d-1 CBD. | |||
| 20 mg·kg-1·d-1, i.p. 1 month | CBD did not alleviate developed thermal or tactile hypersensitivity. | |||
| Costa et al., (2007) [41] | Wistar rats | CCI | 2.5, 5, 10 or 20 mg·kg-1·d-1, oral 7 d | 5, 10 and 20 mg·kg-1·d-1 CBD sig. decreased thermal and mechanical hyperalgesia on Tx day 7. |
| Nociceptive (Inflammatory) Pain | ||||
| Genaro et al., (2017) [70] | Wistar rats | Incision | 0.3, 1, 3, 10 or 30 mg·kg-1, i.p. | 3 mg·kg-1 CBD sig. decreased mechanical allodynia between 30- and 150-min post-Tx; 10 mg·kg-1 CBD sig. decreased mechanical allodynia 60 min post-Tx, only. |
| Hammell et al., (2016) [75] | Sprague-Dawley rats | FCA | 0.6, 3.1, 6.2 or 62.3 mg·kg-1·d-1, t.c. 4 d | 6.2 and 62.3 mg·kg-1 CBD sig. decreased pain-related behaviour on Tx day 4 and thermal hyperalgesia on Tx days 2, 3 and 4. |
| Costa et al., (2007) [41] | Wistar rats | FCA | 20 mg·kg-1·d-1, oral 7 d | CBD sig. decreased thermal and mechanical hyperalgesia on Tx day 7. |
| Costa et al., (2004) [39] | Wistar rats | Carrageenan | 5, 7.5, 10, 20 and 40 mg·kg-1, oral | 5, 7.5, 10, 20 and 40 mg·kg-1·d-1 CBD sig. decreased thermal hyperalgesia 1–5 h post-Tx. |
| Costa et al., (2004) [40] | Wistar rats | Carrageenan | 10 mg·kg-1, oral | CBD sig. decreased thermal hyperalgesia 1 h post-Tx. |
The ‘Treatment Effects’ described are in comparison to a vehicle condition, unless otherwise stated
CBD Cannabidiol, CCI Chronic Constriction Injury, CT Chemotherapy, FCA Freund’s Complete Adjuvant, i.n. Intranasal, i.t. Intrathecal, s.c. Subcutaneous, SNI Spared Nerve Injury, STZ Streptozotocin, t.c. Transcutaneously, Tx Treatment